Altogether, these results demonstrate that proliferating Ki-67+ IIC; CD3+, CD8+, and CD4+ TILs; CD20+ TIL-Bs; and HLA-DR and IFN-γ are positive prognostic markers for NSCLC patients. This evidence concerns the gene CD4 and non-small cell lung carcinoma.